Danaher price target lowered to $285 from $305 at Citi

Citi analyst Patrick Donnelly lowered the firm’s price target on Danaher (DHR) to $285 from $305 and keeps a Buy rating on the shares. Outside of the preannouncements and guidance updates from life science tools and diagnostics names in January, Citi expects key themes to include the cadence and magnitude of the expected recoveries in areas such as China and bioprocessing, the rollout of the China stimulus program, trends within the instrumentation replacement cycle, general biopharma health and its possible impact on clinical trial demand, and the possible effects of the new administration. The firm adjusted numbers for Danaher to reflect currency headwinds.